Scholar Rock is trading at $62.91 (+13.54%) after the FDA approved its spinal muscular atrophy therapy on September 11, 2026, marking its first regulatory approval.
- The injectable treatment, sold as Isembyld, is designed to improve motor function in adults and children already receiving SMA therapies.
- Shares were halted in aftermarket trading, indicating unusually significant activity; broader market gains provided additional support.